Application of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia.
The last decade has seen great strides in the field of cancer immunotherapy, especially the treatment of melanoma. Beginning with the identification of cancer antigens, followed by the clinical application of anti-cancer peptide vaccination, it has now been proven that adoptive T-cell therapy (ACT) using cancer antigen-specific T cells is the most effective option. Despite the apparent clinical efficacy of ACT, the timely preparation of a sufficient number of cancer antigen-specific T cells for each patient has been recognized as its biggest limitation. Currently, therefore, attention is being focused on ACT with engineered T cells produced using cancer antigen-specific T-cell receptor (TCR) gene transfer. With regard to human leukemia, ACT using engineered T cells bearing the leukemia antigen-specific TCR gene still remains in its infancy. However, several reports have provided preclinical data on TCR gene transfer using Wilms' tumor gene product 1 (WT1), and also preclinical and clinical data on TCR gene transfer involving minor histocompatibility antigen, both of which have been suggested to provide additional clinical benefit. In this review, we examine the current status of anti-leukemia ACT with engineered T cells carrying the leukemia antigen-specific TCR gene, and discuss the existing barriers to progress in this area.
Ochi
Toshiki
T
Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan.
Fujiwara
Hiroshi
H
Yasukawa
Masaki
M
D000951:Antigens, Neoplasm / Q000276:immunology*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007938:Leukemia / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology*
D000951:Antigens, Neoplasm; D011948:Receptors, Antigen, T-Cell
Haematologica. 2007 Jan;92(1):72-80
17229638
Blood. 2009 Jan 1;113(1):66-74
18820130
N Engl J Med. 1979 May 10;300(19):1068-73
34792
Expert Opin Ther Targets. 2009 Dec;13(12):1399-410
19821797
Blood. 2009 Jul 16;114(3):535-46
19451549
Blood. 1999 Aug 15;94(4):1201-8
10438707
Curr Opin Immunol. 2009 Apr;21(2):233-40
19304471
Clin Immunol. 2006 May;119(2):135-45
16458072
Cancer Res. 2006 Mar 15;66(6):3331-7
16540688
Blood. 2005 Jul 15;106(2):470-6
15790789
Haematologica. 2010 Jan;95(1):126-34
19679884
Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1457-62
16432223
Nature. 1986 Mar 20-26;320(6059):232-8
2421164
Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90
15365188
J Immunol. 2007 Oct 15;179(8):4959-68
17911580
N Engl J Med. 2009 Jan 29;360(5):447-58
19179314
Science. 2002 Oct 25;298(5594):850-4
12242449
Science. 1997 Jun 13;276(5319):1719-24
9180086
J Clin Invest. 2007 Sep;117(9):2562-9
17710227
Blood. 2009 Jun 25;113(26):6541-8
19389880
Nat Med. 2004 Sep;10(9):909-15
15340416
Annu Rev Immunol. 2005;23:101-25
15771567
Nat Med. 2008 Nov;14(11):1264-70
18978797
Blood. 2001 May 1;97(9):2903-7
11313288
Gene Ther. 2000 Aug;7(16):1369-77
10981663
Am J Hematol. 2009 May;84(5):314-5
19338044
Cancer Res. 2007 Apr 15;67(8):3898-903
17440104
Cancer Res. 2007 Mar 15;67(6):2425-9
17363559
J Immunol. 2005 Apr 1;174(7):4415-23
15778407
Nature. 2005 Jun 30;435(7046):1267-70
15988530
Blood. 2007 Jun 1;109(11):4698-707
17327416
Mol Ther. 2009 Apr;17(4):742-9
19209146
Blood. 2005 Nov 1;106(9):3062-7
16020516
J Immunol. 2003 Sep 15;171(6):3287-95
12960359
Clin Cancer Res. 2006 Feb 15;12(4):1229-36
16489078
Science. 2009 Nov 6;326(5954):818-23
19892975
Cancer Res. 2009 Dec 1;69(23):9003-11
19903853
Blood. 2009 Oct 1;114(14):2888-99
19589923
Cancer Res. 2006 Sep 1;66(17):8878-86
16951205
Blood. 2007 Mar 15;109(6):2331-8
17082316
Blood. 2008 Dec 1;112(12):4371-83
19029455
Blood. 2007 Jan 1;109(1):235-43
16968899
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73
12427970
J Clin Invest. 2008 Jan;118(1):294-305
18060041
Tissue Antigens. 1995 Apr;45(4):223-31
7638857
Haematologica. 2005 Oct;90(10):1415-21
16219579
Blood. 2003 Oct 15;102(8):2892-900
12829610
Blood. 2003 Nov 15;102(10):3530-40
12869497
Tissue Antigens. 1996 Feb;47(2):93-101
8851721
J Immunol. 2008 Oct 1;181(7):5128-36
18802117
J Exp Med. 2004 Apr 5;199(7):885-94
15051765
Science. 2006 Oct 6;314(5796):126-9
16946036
Nat Med. 2000 Sep;6(9):1018-23
10973322
Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17469-74
19805141
Gene Ther. 2009 May;16(5):620-8
19242528
N Engl J Med. 1981 Jun 18;304(25):1529-33
7015133
Gene Ther. 2008 May;15(9):695-9
18288212
Blood. 2000 Jan 1;95(1):286-93
10607714
Lancet Oncol. 2009 May;10(5):489-500
19345145
J Immunol. 1999 Jul 1;163(1):507-13
10384155
J Immunother. 2008 Jan;31(1):1-6
18157006
J Immunol. 2008 Jun 1;180(11):7736-46
18490778
J Immunol. 2007 Nov 1;179(9):5803-10
17947653
N Engl J Med. 2008 Jun 19;358(25):2698-703
18565862